Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a leading pharmaceutical company based in China, has announced that it has received approval from the US Food and Drug Administration (FDA) to commence clinical trials for its KH658 eye injection. The drug is designed for the treatment of neovascular (wet) age-related macular degeneration (nAMD).
KH658 utilizes a novel adeno-associated virus (AAV) as a delivery vector to inhibit the growth of neovascular lesions associated with nAMD. The drug works by continuously expressing anti-VEGF protein, which slows down the progression of the disease. KH658 is anticipated to offer long-term benefits to patients, potentially through a single administration.- Flcube.com
